Monitor the company's cash burn rate and any future prospectus supplements indicating further ATM sales. The low stock price ($0.539 per ADS) suggests continued dilution pressure. Watch for any announcements regarding pipeline progress or financing alternatives that could reduce reliance on ATM offerings.
Price Chart
Executive Summary
RedHill Biopharma filed a 424B5 prospectus supplement to increase the maximum aggregate offering amount of ADSs available for sale under its existing at-the-market (ATM) agreement with H.C. Wainwright. The company may now offer and sell up to $2,587,409 in additional ADSs, subject to the one-third public float limit under General Instruction I.B.5 of Form F-3. This filing signals ongoing capital needs and potential dilution for existing shareholders.
Key Facts
- RedHill Biopharma filed a 424B5 prospectus supplement to increase the maximum aggregate offering amount of ADSs under its ATM agreement with H.C. Wainwright.
- The company may now offer and sell up to $2,587,409 in additional ADSs, subject to the one-third public float limit under General Instruction I.B.5 of Form F-3.
- As of the filing date, the aggregate market value of outstanding ordinary shares held by non-affiliates was $7,911,299.70, based on 87,903,331,000 ordinary shares outstanding held by non-affiliates and a per ADS price of $0.90.
- The company had previously sold 54,954 ADSs under the Sales Agreement for aggregate gross proceeds of $49,690.55 during the 12 calendar months prior to the filing.
- The last reported sale price of the ADSs on Nasdaq on October 9, 2026 was $0.539 per ADS, down from the $0.90 reference price used for the public float calculation.
- The offering is conducted through H.C. Wainwright & Co., LLC as sales agent.
Financial Impact
Up to $2,587,409 in additional ADSs may be sold under the ATM agreement, representing approximately 32.7% of the current public float of $7,911,299.70. The company has already sold $49,690.55 in ADSs under this program.
Risk Factors
- Potential dilution from additional ADS sales under the ATM program.
- Low stock price and small public float may limit the company's ability to raise capital without significant dilution.
- The company's reliance on ATM offerings indicates ongoing cash needs, which could pressure the stock if pipeline catalysts fail to materialize.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001178913-26-004763 |
| Document: 0001178913-26-004763-index-headers.html | 0001178913-26-004763 |
| Document: 0001178913-26-004763-index.html | 0001178913-26-004763 |
| Document: 0001178913-26-004763.txt | 0001178913-26-004763 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers